Cancer and reproductive health Cancer
Conditions
Interventions
This is a multi-centre clinical prospective observational cohort study open to all clinical centres directly involved in the care of teenage and young adults (aged 13-25 years) with cancer.
Potentia
Sponsors
University of Edinburgh and NHS Lothian
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Current inclusion criteria as of 28/01/2025: 1. Willing and able to provide written informed consent (including by parent/guardian where appropriate) 2. Aged 13-25 years 3. First cancer diagnosis or relapse of same diagnosis 4. Requires cancer treatment with targeted, immunological and cell-based therapies (surgery, chemotherapy and radiotherapy are permitted if part of this treatment or if the initial treatment plan changes) Previous inclusion criteria: 1. Willing and able to provide written informed consent (including by parent/guardian where appropriate). 2. Aged 13-25 years old 3. First cancer diagnosis 4. Requires cancer treatment (surgery, chemotherapy including targeted therapies, radiotherapy, bone marrow transplant).
Exclusion criteria
Exclusion criteria: 1. Inability to provide informed consent 2. Does not require cancer treatment 3. Where treatment is not given with the intention of cure or long-term survival
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of reproductive failure and of gonadal dysfunction measured using diagnosis/treatment regimen at 2 years after diagnosis | — |
Secondary
| Measure | Time frame |
|---|---|
| Current secondary outcome measures as of 08/05/2025: Uptake of fertility preservation services, and long-term reproductive outcomes including ongoing ovulation/spermatogenesis, conception, age at menopause, and the need for hormone replacement. The prevalence of reproductive failure and of gonadal dysfunction by diagnosis/treatment regimen at 1 and 5 years after diagnosis. A blood sample is collected at baseline, and 1-, 2-, 3- and 5-year follow-up. In females, anti-Mullerian hormone (AMH) levels will be measured in serum, data will be analysed in conjunction with follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. For males, Inhibin B will be measured in serum. Inhibin B data will be analysed in conjunction with FSH/LH/testosterone levels. _____ Previous secondary outcome measures: Uptake of fertility preservation services, and long-term reproductive outcomes including ongoing ovulation/spermatogenesis, conception, age at menopause, and the need for hormone replacement. The prevalence of reproductive failure and of gonadal dysfunction by diagnosis/treatment regimen at 1 and 3 years after diagnosis. A blood sample is collected at baseline, and 1-, 2- and 3-year follow-up. In females, anti-Mullerian hormone (AMH) levels will be measured in serum, data will be analysed in conjunction with follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol (E2) levels. For males, Inhibin B will be measured in serum. Inhibin B data will be analysed in conjunction with FSH/LH/testosterone levels. | — |
Countries
England, Scotland, United Kingdom, Wales
Contacts
Public ContactAudrey Kuchnowski
Outcome results
None listed